ResearchSafe

Compounded Tirzepatide (Compounded Tirzepatide (503B Pharmacy))

Category: Weight Management. Status: Compounded medication.

Compounded tirzepatide offers the most potent dual GLP-1/GIP agonism for weight loss through telemedicine clinics. Provides even greater weight loss efficacy than semaglutide by targeting two incretin pathways simultaneously.

How it works

Dual agonist of both GLP-1 and GIP receptors. GLP-1 activation suppresses appetite and slows gastric emptying. GIP activation enhances fat metabolism, improves insulin sensitivity, and may protect against muscle loss.

Key facts

  • Molecular weight: 4813.45 Da
  • Half-life: ~5 days
  • Bioavailability: ~80% subcutaneous
  • Storage: Refrigerate 2-8°C.

Dosing overview

  • Typical dose: 2.5-15 mg
  • Frequency: Once weekly
  • Duration: 12-52+ weeks
  • Route: Subcutaneous injection

Protocol notes

  • Start at 2.5 mg once weekly for ~4 weeks (a tolerance dose), then increase to 5 mg.
  • Step up by ~2.5 mg roughly every 4 weeks toward the effective dose (up to 15 mg) as tolerated.
  • Settle at the lowest dose that maintains appetite control and weight goals.
  • Keep the same injection day each week.

Reported benefits

  • Superior weight loss (20-25%)
  • Dual incretin pathway activation
  • Better muscle preservation
  • Improved A1c
  • Cardiovascular protection
  • Reduced insulin resistance

Possible side effects

  • Nausea
  • Diarrhea
  • Decreased appetite
  • Vomiting
  • Constipation
  • Injection site reactions

Research

  • SURMOUNT-1 trial (2023): Tirzepatide 15mg achieved 22.5% mean weight loss at 72 weeks, significantly outperforming semaglutide head-to-head.

Compare Compounded Tirzepatide

Community discussions about Compounded Tirzepatide

Research and educational reference only. Not medical advice.